MRK vs PGNY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
PGNY exhibits exceptional fundamental health, highlighted by a perfect Piotroski F-Score of 9/9 and a negligible Debt/Equity ratio of 0.05. While the stock has suffered significant long-term price decay and currently faces bearish technical trends and insider selling, the valuation is highly attractive on a forward basis with a Forward P/E of 8.53. The company's consistent track record of earnings beats and strong earnings growth (20.6% YoY) suggests a disconnect between market sentiment and operational performance. The current price of $17.93 sits comfortably below the growth-based intrinsic value of $19.77 and well below analyst targets.
Compare Another Pair
Related Comparisons
MRK vs PGNY: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and Progyny, Inc. (PGNY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.